Biomarin Pharmaceutical (BMRN) Total Debt (2012 - 2026)

Biomarin Pharmaceutical's Total Debt history runs 14 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• Quarterly Total Debt changed N/A year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (changed N/A YoY) and the FY2025 annual result came in at $597.2 million, changed N/A from the prior year.
• Total Debt was $1.4 billion for Q1 2026 at Biomarin Pharmaceutical, up from $597.2 million in the prior quarter.
• Across five years, Total Debt topped out at $1.4 billion in Q1 2026 and bottomed at $15.9 million in Q4 2022.
• A 5-year average of $405.4 million and a median of $493.9 million in 2023 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2022 — Total Debt plunged 66.98% — and 2023, when it surged 3001.27%.
• Biomarin Pharmaceutical's Total Debt stood at $15.9 million in 2022, then jumped by 3001.27% to $493.9 million in 2023, then gained by 0.19% to $494.8 million in 2024, then grew by 20.68% to $597.2 million in 2025, then surged by 139.51% to $1.4 billion in 2026.
• Business Quant data shows BMRN's Total Debt at $1.4 billion in Q1 2026, $597.2 million in Q4 2025, and $494.8 million in Q2 2024.